Sanofi strengthens in Pompe disease with Maze tie-up

Maze Therapeutics, a privately-held Californian company translating genetic insights into new precision medicines, has announced the signing of an exclusive worldwide license agreement with French pharma major Sanofi (Euronext: SAN).

The deal is for Maze’s glycogen synthase 1 (GYS1) program, including clinical candidate MZE001, which is currently in development for the treatment of Pompe disease and other potential indications.

"The ideal partner to continue the advancement of MZE001"Sanofi is already the market leader in Pompe disease, a rare, inherited disorder caused by mutations in the gene coding for acid alpha- glucosidase, which lead to the buildup of glycogen in skeletal muscle, respiratory muscle and cardiac muscle tissues resulting in progressive weakness and respiratory compromise.